Crisantaspase - Jazz Pharmaceuticals

Drug Profile

Crisantaspase - Jazz Pharmaceuticals

Alternative Names: E. chrisanthemi L-asparaginase - EUSA; Asparaginase Erwinia chrysanthemi; Erwina chrisanthemi L-asparaginase; Erwinase; Erwinaze; Erwinia asparaginase; Erwinia L-asparaginase - EUSA; OP-01

Latest Information Update: 10 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Health Protection Agency
  • Developer EUSA Pharma; Jazz Pharmaceuticals plc; Ohara Pharmaceutical
  • Class Amidohydrolases; Cytostatics
  • Mechanism of Action Amidohydrolase stimulants; Aspartate-ammonia ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Precursor cell lymphoblastic leukaemia-lymphoma
  • Registered Lymphoma

Most Recent Events

  • 19 Dec 2016 Registered for Acute lymphoblastic leukaemia in Japan (IM)
  • 19 Dec 2016 Registered for Lymphoma in Japan (IM)
  • 22 Feb 2016 Jazz Pharmaceuticals has protection for Erwinase®, through orphan drug exclusivity, in USA (Jazz Pharmaceuticals, Form 10-K, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top